The ninth FDA clearance for the Swoop Portable MR Imaging system is for new software that enables significant scan time reduction for brain MRI scans.
The Swoop Portable MR Imaging system has garnered another FDA 510(k) clearance for new software that may facilitate more expedient diagnosis of neurological conditions.
The updated software reportedly offers significant reduction of scan times, facilitating use of the device’s ultra-low-field magnetic resonance imaging (MRI) capabilities in acute care settings, according to Hyperfine, the manufacturer of the Swoop Portable MR Imaging system.
A newly FDA-cleared software update for the Swoop Portable MR Imaging system facilitates significantly reduced scan times for low-field MRI brain imaging, according to Hyperfine, the manufacturer of the MRI system. (Image courtesy of Hyperfine.)
“Timely MR brain imaging is essential for clinicians making critical treatment decisions, particularly in acute neurological episodes like strokes. We have been an active site in the ACTION PMR study assessing the use of the Swoop® system in stroke diagnosis, and this latest software will help the Swoop® system more seamlessly integrate into stroke workflows,” noted Adnan Siddiqui, M.D., Ph.D., a professor and vice-chairman in the Department of Neurosurgery at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences.
Hyperfine added that the reduced acquisition time for MRI sequences with the new software may help mitigate the impact of patient motion on brain scan quality.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Can Deep Learning Radiomics with bpMRI Bolster Accuracy for Prostate Cancer Prognosis?
January 22nd 2025An emerging deep learning radiomics model based on biparametric MRI (bpMRI) offered a 14 to 17 percent higher AUC range than PI-RADS scoring for predicting the aggressiveness of prostate cancer, according to new research findings.